| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8450311 | NOVARTIS | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
May, 2029
(5 years from now) | |
| US9114168 | NOVARTIS | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
May, 2029
(5 years from now) | |
Moxeza is owned by Novartis.
Moxeza contains Moxifloxacin Hydrochloride.
Moxeza has a total of 2 drug patents out of which 0 drug patents have expired.
Moxeza was authorised for market use on 19 November, 2010.
Moxeza is available in solution/drops;ophthalmic dosage forms.
The generics of Moxeza are possible to be released after 29 May, 2029.
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 19 November, 2010
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of MOXEZA before it's drug patent expiration?
More Information on Dosage
MOXEZA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic